Compare TECH & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TECH | AXSM |
|---|---|---|
| Founded | 1976 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 8.6B |
| IPO Year | 1995 | 2015 |
| Metric | TECH | AXSM |
|---|---|---|
| Price | $55.53 | $206.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 17 |
| Target Price | $71.82 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 1.8M | 525.9K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.62% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $1,219,635,000.00 | N/A |
| Revenue This Year | $2.49 | $57.24 |
| Revenue Next Year | $6.40 | $55.88 |
| P/E Ratio | $106.04 | ★ N/A |
| Revenue Growth | ★ 5.23 | N/A |
| 52 Week Low | $46.05 | $96.09 |
| 52 Week High | $72.16 | $193.49 |
| Indicator | TECH | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 75.10 |
| Support Level | $49.55 | $148.87 |
| Resistance Level | $58.04 | N/A |
| Average True Range (ATR) | 2.73 | 8.30 |
| MACD | -0.40 | 1.27 |
| Stochastic Oscillator | 38.90 | 74.89 |
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.